MedTrace Logo

Frequency of Metabolic Dysfunction Associated Fatty Liver Disease in Patients With Acute Coronary Syndromes

NCT06456970 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 140

Last updated 2024-06-13

No results posted yet for this study

Summary

Aim of the research is to assess frequency of MAFLD among patients with acute coronary syndromes (ACS).

Conditions

Interventions

DEVICE

fibroscan

Fibroscan examination with controlled attenuation parameter"CAP" (Echosens FibroScan ® Compact 530) for evaluation of steatosis and its degree (by CAP score) and fibrosis stage by liver stiffness measurement(LSM)

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Taiseer Mohamed Kamal El Deen, resident · Assiut University

  • Waleed Attia Hassan, A.professor · Assiut University

  • Sahar Mohammed Hassany, professor · Assiut University

  • Mohamed Osman Abdelhameed, Lecturer · Assiut University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-01
Primary Completion
2025-07-01
Completion
2026-07-01

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06456970 on ClinicalTrials.gov